Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data
But what is BPC-157, and how does it work
BPC-157 is studied in laboratory models involving gastrointestinal biology, musculoskeletal tissue research, endothelial function, inflammatory signaling, extracellular matrix remodeling, vascular biology, and neuroscience
Reduced iHSP72 levels in skeletal muscle and other insulin-responsive tissues are strongly associated with insulin resistance, a defining feature of T2DM
The timing and intensity of gastrointestinal side effects differ by product and person, so patients should choose a time that best manages their symptoms whilst maintaining consistent adherence
